Question explored with the scientific record
Conversation so far
- 1 Side effects of amalodipine
- 2 Are there safer alternatives like ACE inhibitors or ARBs for similar BP goals?
Answered on this page ↓
Are there safer alternatives like ACE inhibitors or ARBs for similar BP goals?
The short version: ACE inhibitors and ARBs match amlodipine for blood pressure control and have a different side-effect profile, but the evidence here is too thin to call one clearly safer.
The evidence here is mostly manufacturer-funded combination studies from 2005-2017 [1, 2, 14]. They compare ACE/ARB plus amlodipine against amlodipine alone, not ACE/ARB alone against amlodipine alone. That is a different question than the one you asked.
What the evidence does show: the ATAR study (2008, N=222) found the amlodipine-ramipril combination caused edema in 7.6% of patients versus 18.7% for amlodipine alone [2]. The VAST study (2005) found valsartan plus hydrochlorothiazide matched amlodipine for blood pressure reduction with fewer side effects [14]. The MARVAL trial (2006, cited in [26]) found valsartan reduced urine protein by 44% versus 8% for amlodipine in diabetics, a kidney-protective effect beyond blood pressure.
The missing piece: no trial here compares ACE inhibitor or ARB alone against amlodipine alone for hard outcomes like heart attack or death. The 2003 NEJM study [17] compared ACE inhibitors against diuretics, not against amlodipine. The 2014 JAMA study [25] showed ACE/ARB use in kidney disease reduced dialysis risk by 6% but increased hyperkalemia hospitalizations from 6.7 to 9.2 per 100 patients.
| Comparison | BP reduction | Edema rate | Kidney protection |
|---|---|---|---|
| Amlodipine alone | -15.8/-8.6 mmHg [2] | 18.7% [2] | None shown |
| Amlodipine + ramipril | -20.8/-11.7 mmHg [2] | 7.6% [2] | Not tested |
| Valsartan + HCTZ | -27.6/-10.8 mmHg [14] | Lower than amlodipine [14] | Not tested |
| ARB vs amlodipine (diabetics) | Similar [26] | Lower [26] | ARB superior [26] |
My call: ACE inhibitors and ARBs provide comparable blood pressure control with less edema and added kidney protection in diabetics, but the evidence here does not compare them head-to-head against amlodipine for long-term mortality. Confidence: moderate for blood pressure equivalence, low for long-term safety comparison.
Sources examined 26
-
Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation
A comprehensive safety evaluation of the fixed-dose combination perindopril arginine and amlodipine besylate for hypertension, synthesizing six randomized trials and numerous observational studies to conclude that its safety profile largely mirrors its individual components, wit…
DOI: 10.1080/14740338.2018.1397129 -
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study
This study evaluates the efficacy and tolerability of a fixed-dose combination of amlodipine and ramipril compared to amlodipine monotherapy in patients with essential hypertension over an 18-week period, finding that the combination therapy significantly reduces blood pressure …
DOI: 10.1016/j.clinthera.2008.09.008 -
Calcium Antagonists for Treatment of Diabetes-Associated Hypertension
This study investigates the metabolic and renal effects of long-term amlodipine therapy in hypertensive patients with diabetes mellitus compared to those with essential hypertension, finding that while blood pressure significantly decreased, there were no adverse effects on meta…
DOI: 10.1093/ajh/7.1.36 -
Use of calcium‐channel blockers in pediatric renal transplant recipients
This study compares the efficacy and side effects of two calcium channel blockers, nifedipine and amlodipine, in treating hypertension in pediatric renal transplant recipients, finding both to be effective but with amlodipine associated with fewer adverse effects.
DOI: 10.1034/j.1399-3046.1999.00056.x -
Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering: Amlodipine and Candesartan Trial in Yokohama (ACTY)
This study investigates the effects of combination therapy with candesartan and amlodipine on blood pressure control and target organ function in Japanese patients with essential hypertension who did not achieve target blood pressure levels during monotherapy, finding significan…
DOI: 10.3109/10641963.2012.681081 -
Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment
A study employing invasive central hemodynamic measurements and 24-hour ambulatory blood pressure monitoring in hypertensive patients to evaluate the long-term hemodynamic effects and 24-hour BP control of amlodipine, demonstrating reduced total peripheral resistance without adv…
DOI: 10.1016/0002-9149(94)90274-7 -
Amlodipine Therapy Corrects Renal Abnormalities Encountered in the Hypertensive State
This study investigates the effects of amlodipine therapy on renal function in patients with essential hypertension, demonstrating significant improvements in glomerular filtration rate and renal plasma flow without adverse changes in body fluid composition.
DOI: 10.1016/s0272-6386(87)80191-9 -
Evaluation of Amlodipine Dosing for Conversion of Nifedipine Extended-Release to Amlodipine in the Treatment of Hypertension
This study evaluates the appropriate dosing of amlodipine when converting patients from nifedipine extended-release to amlodipine for hypertension treatment, finding that both medications provide similar blood pressure control with amlodipine dosages of 5 or 10 mg once daily bei…
DOI: 10.1345/aph.18177 -
Long term effects of amlodipine on heart rate and heart rate variability in essential hypertensives
A multicenter randomized, double-blind, placebo-controlled dose–response trial evaluating LU 135252, an endothelin receptor antagonist, in adults with moderate hypertension, showing dose-dependent reductions in diastolic and systolic blood pressure compared with placebo.
DOI: 10.1016/s0895-7061(01)01390-5 -
Hypertension Control in the Elderly with Amlodipine
This study evaluates the effectiveness and safety of amlodipine as an antihypertensive treatment in elderly patients, highlighting its benefits in reducing cardiovascular events and its tolerability compared to other antihypertensive agents.
DOI: 10.1185/0300799009117005 -
Efficacy of Candesartan Cilexetil Alone or in Combination With Amlodipine and Hydrochlorothiazide in Moderate-to-Severe Hypertension
Candesartan cilexetil lowers blood pressure effectively as monotherapy and when combined with amlodipine and/or hydrochlorothiazide in moderate-to-severe essential hypertension, with withdrawal confirming its sustained antihypertensive contribution and 24-hour action.
DOI: 10.1161/01.hyp.36.3.454 -
Felodipine and grapefruit juice
This study investigates the effects of various antihypertensive medications on insulin sensitivity and glucose tolerance, revealing that while some calcium channel blockers do not significantly impair these metabolic functions, certain beta-blockers and diuretics may adversely a…
DOI: 10.2165/00042310-199404050-00006 -
Cardiovascular Effects of Azelnidipine in Comparison with Those of Amlodipine Assessed in the Halothane‐Anaesthetized Dog
This study compares the cardiovascular effects of azelnidipine and amlodipine in halothane-anesthetized dogs, finding that azelnidipine has a similar hypotensive effect without causing reflex tachycardia, unlike amlodipine.
DOI: 10.1111/j.1742-7843.2009.00478.x -
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study
The VAST study demonstrates that combination therapy with valsartan and hydrochlorothiazide is more effective than amlodipine monotherapy in reducing systolic blood pressure in hypertensive patients with additional cardiovascular risk factors, while also showing better tolerabil…
DOI: 10.1016/j.clinthera.2005.05.006 -
Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine
A multicenter prospective open-label study in hypertensive patients uncontrolled by ARB plus low-dose amlodipine compared high-dose amlodipine (10 mg) versus adding indapamide to the regimen, finding both approaches effective over 6 months with greater long-term BP reduction for…
DOI: 10.1080/10641963.2017.1334798 -
Risk factors for foot ulcers in patients with diabetes mellitus - A short report from Vellore, South India
A South Indian hospital-based case-control study identifies insulin therapy, peripheral neuropathy, pre-ulcer states, callus, and deformity as risk factors for diabetic foot ulcers in adults with diabetes, while hypertension (in patients on ACE inhibitors) appeared protective, h…
DOI: 10.4103/0970-0218.62582 -
A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly
This study compares the outcomes of angiotensin-converting enzyme (ACE) inhibitors and diuretics in treating hypertension among elderly patients, finding that ACE inhibitors lead to better cardiovascular outcomes, particularly in men.
DOI: 10.1056/NEJMoa021716 -
P2638Plasma trimethylamine-N-oxide is associated with atrial fibrillation
This study investigates the relationship between pentraxin-3 (PTX-3) and high-sensitivity C-reactive protein (hs-CRP) plasma levels in hypertensive patients with endothelial dysfunction, finding that treatment with ACE inhibitors and ARBs significantly lowers PTX-3 levels compar…
DOI: 10.1093/eurheartj/ehx502.p2638 -
Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor
This study developed a specific direct radioimmunoassay for measuring angiotensin II levels in human plasma, revealing its dynamics in various types of hypertension and the effects of ACE inhibitors.
DOI: 10.1016/s0162-3109(99)00090-9 -
A parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertension
This study compares the efficacy and safety of enalapril and captopril in treating moderate-to-severe essential hypertension in patients already on hydrochlorothiazide, demonstrating that enalapril is more effective with fewer adverse effects.
DOI: 10.1016/0002-8703(85)90650-7 -
Green Asparagus ( Asparagus officinalis ) Prevented Hypertension by an Inhibitory Effect on Angiotensin-Converting Enzyme Activity in the Kidney of Spontaneously Hypertensive Rats
This study investigates the antihypertensive effects of green asparagus (Asparagus officinalis) in spontaneously hypertensive rats (SHR) and identifies 2″-hydroxynicotianamine as a key angiotensin-converting enzyme (ACE) inhibitor responsible for these effects.
DOI: 10.1021/jf3041066 -
A reappraisal of renin–angiotensin system blockade on microalbuminuria development
This study critically evaluates the effectiveness of renin-angiotensin system blockade in preventing microalbuminuria and its implications for cardiovascular risk, suggesting that such treatments may not provide unique benefits compared to blood pressure control alone.
DOI: 10.1097/HJH.0b013e32834e997f -
Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
Post hoc analysis of the GEMINI trial showing that concomitant insulin sensitizer use modulates the differential effects of carvedilol versus metoprolol tartrate on insulin resistance and HbA1c in type 2 diabetes with hypertension, with carvedilol generally preserving or improvi…
DOI: 10.1111/j.1464-5491.2007.02151.x -
HYPERTENSION IN HEMODIALYSIS PATIENTS: Drug Therapy for Hypertension in Hemodialysis Patients
A comprehensive review of hypertension management in hemodialysis patients, summarizing prevalence, pharmacologic options (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and other agents), their effects on blood pressure, left ventricular hypertrophy, mortality, …
DOI: 10.1111/j.0894-0959.2004.17329.x -
Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia
This study investigates the effectiveness and safety of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in reducing the risk of long-term dialysis and mortality in patients with predialysis advanced chronic kidney disease, hypertensio…
DOI: 10.1001/jamainternmed.2013.12700 -
The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy
An evidence-based narrative review detailing how angiotensin receptor blockers (ARBs) provide renoprotection in diabetic nephropathy beyond blood pressure reduction, summarizing key randomized trials showing BP-independent reductions in albuminuria and slowed progression to ESRD…
DOI: 10.3810/pgm.2011.05.2289